

Devyser terminates liquidity guarantee agreement

Devyser Diagnostics AB (publ) today announces that the company has terminated the liquidity guarantee agreement with Carnegie Investment Bank. The agreement expires on November 29, 2024.

The purpose of a liquidity guarantee agreement is to improve share liquidity and reduce volatility. Devyser deems that the trading and liquidity of the company share is adequate and therefore, the need for a liquidity guarantee agreement is limited.

For more information, please contact:

Fredrik Alpsten, CEO

E-mail: fredrik.alpsten@devyser.com

Telephone: +46 70 667 31 06

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.